Demyelinating Polyneuropathy disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: DMY001 MIFTS: 43	Demyelinating Polyneuropathy Categories: Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Demyelinating Polyneuropathy

MalaCards integrated aliases for Demyelinating Polyneuropathy:

Name: Demyelinating Polyneuropathy ¹² ¹⁵

Peripheral Demyelinating Neuropathy ¹² ⁷¹

Demyelinating Peripheral Neuropathy ⁶

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Neuronal diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:5214

NCIt ⁴⁹ C27062

SNOMED-CT ⁶⁷ 23414001

UMLS ⁷¹ C0270922

Sources

Summaries for Demyelinating Polyneuropathy

MalaCards based summary : Demyelinating Polyneuropathy, also known as peripheral demyelinating neuropathy, is related to guillain-barre syndrome and multifocal motor neuropathy. An important gene associated with Demyelinating Polyneuropathy is PMP22 (Peripheral Myelin Protein 22), and among its related pathways/superpathways are Cell adhesion molecules (CAMs) and Spinal Cord Injury. The drugs Immunoglobulin G and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include t cells, spinal cord and testes, and related phenotypes are behavior/neurological and homeostasis/metabolism

Sources

Related Diseases for Demyelinating Polyneuropathy

Diseases in the Demyelinating Polyneuropathy family:

Subacute Inflammatory Demyelinating Polyneuropathy	Acute and Subacute Inflammatory Demyelinating Polyneuropathy
Chronic Acquired Demyelinating Polyneuropathy

Diseases related to Demyelinating Polyneuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 449)

#	Related Disease	Score	Top Affiliating Genes
1	guillain-barre syndrome	33.1	PMP22 NFASC MAG HP ALB
2	multifocal motor neuropathy	31.6	FCGR2B CNTN2
3	polyradiculoneuropathy	31.3	PMP22 NFASC MAG CNTN1 ALB
4	sensory peripheral neuropathy	31.1	PMP22 NGF MAG ALB
5	mononeuropathy	31.0	PMP22 NGF MAG
6	mononeuritis multiplex	31.0	PMP22 MAG
7	chronic polyneuropathy	30.9	PMP22 MAG FCGR2B
8	miller fisher syndrome	30.8	PMP22 NFASC MAG CNTN1
9	demyelinating disease	30.7	PMP22 NGF MMP9 MAG
10	diabetic neuropathy	30.7	PMP22 NGF GDNF
11	median neuropathy	30.6	TTR PMP22
12	autoimmune neuropathy	30.5	PMP22 NFASC MAG FCGR2B CNTN1
13	chronic graft versus host disease	30.5	TNFSF13B ALB
14	neuritis	30.4	PMP22 MMP9 MAG GDNF
15	charcot-marie-tooth disease	30.3	TTR PMP22 NGF NFASC MAG GDNF
16	autoimmune peripheral neuropathy	30.3	MAG AIRE
17	optic nerve disease	30.3	NGF MAG ALB AIF1
18	autonomic neuropathy	30.3	TTR NGF ALB
19	polyneuropathy	30.2	TTR PMP22 NGF NFASC MAG IFNA2
20	neuromuscular disease	30.2	PMP22 MAG GDNF ALB
21	peripheral nervous system disease	30.2	TTR PMP22 NGF NFASC MAG GDNF
22	anemia, x-linked, with or without neutropenia and/or platelet abnormalities	30.0	TTR IFNA2 HP ALB
23	thrombocytopenic purpura, autoimmune	30.0	IFNA2 FCGR2B CD52
24	corneal disease	30.0	NGF MMP9 ALB
25	metachromatic leukodystrophy	29.9	MAG GDNF ALB
26	hydrocephalus	29.9	TTR PTGDS NGF GDNF
27	central nervous system disease	29.8	TTR NGF MMP9 ALB
28	meningitis	29.7	PTGDS MMP9 GDNF ALB
29	meningoencephalitis	29.7	NGF GDNF CLDN5 ALB
30	thrombocytopenia	29.7	TNFSF13B MMP9 IFNA2 HP FCGR2B ALB
31	malaria	29.4	TTR TNFSF13B MMP9 HP FCGR2B ALB
32	multiple sclerosis	28.8	TNFSF13B PTGDS NGF MMP9 MAG CD52
33	peripheral demyelinating neuropathy, central dysmyelination, waardenburg syndrome, and hirschsprung disease	12.9
34	chronic acquired demyelinating polyneuropathy	12.5
35	subacute inflammatory demyelinating polyneuropathy	12.5
36	chronic inflammatory demyelinating polyradiculoneuropathy	12.5
37	acute and subacute inflammatory demyelinating polyneuropathy	12.4
38	guillain-barre syndrome, familial	12.3
39	lewis-sumner syndrome	11.7
40	neuropathy, hereditary, with liability to pressure palsies	11.6
41	charcot-marie-tooth disease, axonal, type 2e	11.5
42	neurodevelopmental disorder with central and peripheral motor dysfunction	11.4
43	mannosidosis, beta a, lysosomal	11.3
44	canomad syndrome	11.3
45	charcot-marie-tooth disease, axonal, type 2a1	11.3
46	charcot-marie-tooth disease and deafness	11.3
47	charcot-marie-tooth disease, type 4a	11.3
48	marinesco-sjogren syndrome	11.3
49	charcot-marie-tooth disease, x-linked dominant, 6	11.3
50	charcot-marie-tooth disease, x-linked dominant, 1	11.3

Graphical network of the top 20 diseases related to Demyelinating Polyneuropathy:

Sources

Symptoms & Phenotypes for Demyelinating Polyneuropathy

MGI Mouse Phenotypes related to Demyelinating Polyneuropathy:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	behavior/neurological	MP:0005386	10.21	AIRE CNTN1 CNTN2 FCGR2B GAS6 GDNF
2	homeostasis/metabolism	MP:0005376	10.13	AIF1 AIRE ALB FCGR2B GAS6 HP
3	cardiovascular system	MP:0005385	10.1	AIF1 ALB CLDN5 FCGR2B GAS6 GDNF
4	immune system	MP:0005387	10	AIF1 AIRE ALB FCGR2B GAS6 GDNF
5	mortality/aging	MP:0010768	9.97	AIRE ALB CLDN5 CNTN1 FCGR2B GAS6
6	digestive/alimentary	MP:0005381	9.91	AIRE ALB CNTN1 FCGR2B GDNF MMP9
7	nervous system	MP:0003631	9.77	AIF1 AIRE CLDN5 CNTN1 CNTN2 FCGR2B
8	renal/urinary system	MP:0005367	9.17	ALB FCGR2B GAS6 GDNF HP MMP9

Sources

Drugs & Therapeutics for Demyelinating Polyneuropathy

Drugs for Demyelinating Polyneuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 52)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Immunoglobulin G

Phase 4

Prednisone

Approved, Vet_approved

Phase 3

53-03-2

5865

Glycine

Approved, Nutraceutical, Vet_approved

Phase 3

56-40-6

750

Pharmaceutical Solutions

Phase 3

rituximab

Approved

Phase 2

174722-31-7

10201696

Prednisolone phosphate

Approved, Vet_approved

Phase 1, Phase 2

302-25-0

Mesna

Approved, Investigational

Phase 1, Phase 2

3375-50-6

598

Methylprednisolone

Approved, Vet_approved

Phase 1, Phase 2

83-43-2

6741

Methylprednisolone hemisuccinate

Approved

Phase 1, Phase 2

2921-57-5

Sargramostim

Approved, Investigational

Phase 1, Phase 2

83869-56-1, 123774-72-1

Lenograstim

Approved, Investigational

Phase 1, Phase 2

135968-09-1

Prednisolone acetate

Approved, Vet_approved

Phase 1, Phase 2

52-21-1

Prednisolone

Approved, Vet_approved

Phase 1, Phase 2

50-24-8

5755

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 2

59-30-3

6037

Prednisolone hemisuccinate

Experimental

Phase 1, Phase 2

2920-86-7

Micronutrients

Phase 2

Trace Elements

Phase 2

Alpha-lipoic Acid

Phase 2

Vitamins

Phase 2

Vitamin B Complex

Phase 2

Antioxidants

Phase 2

Thioctic Acid

Phase 2

Folate

Phase 2

Nutrients

Phase 2

Vitamin B9

Phase 2

Hormone Antagonists

Phase 1, Phase 2

Hormones

Phase 1, Phase 2

Antineoplastic Agents, Hormonal

Phase 1, Phase 2

glucocorticoids

Phase 1, Phase 2

Anti-Inflammatory Agents

Phase 1, Phase 2

Protective Agents

Phase 1, Phase 2

Autoantibodies

Phase 2

Antineoplastic Agents, Immunological

Phase 2

polysaccharide-K

Phase 1, Phase 2

Gastrointestinal Agents

Phase 1, Phase 2

Methylprednisolone Acetate

Phase 1, Phase 2

Antibodies, Monoclonal

Phase 1, Phase 2

Neuroprotective Agents

Phase 1, Phase 2

Antiemetics

Phase 1, Phase 2

Thymoglobulin

Phase 1, Phase 2

Antilymphocyte Serum

Phase 1, Phase 2

Antibodies

Phase 2

Immunoglobulins, Intravenous

Phase 2

Rho(D) Immune Globulin

Phase 2

gamma-Globulins

Phase 2

Immunoglobulins

Phase 2

Immunologic Factors

Phase 2

Fibrinolytic Agents

Phase 2

Tissue Plasminogen Activator

Phase 2

Plasminogen

Phase 2

Interventional clinical trials:

(show all 45)

#	Name	Status	NCT ID	Phase	Drugs
1	Treatment With Gamunex 10% Intravenous Immunoglobulin (IVIg) for Patients With Demyelination and Diabetes Mellitus: A Blinded, Placebo-Controlled Crossover Pilot Study	Unknown status	NCT02372149	Phase 4	10% intravenous immunoglobulin (IVIg);0.9% sodium chloride
2	Randomized Study of Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP	Active, not recruiting	NCT03684018	Phase 4
3	Prospective, Open-Label, Phase IIIb Study Evaluating the Safety, Tolerability and Efficacy of Panzyga® in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Administered at Standard and High Infusion Rates	Unknown status	NCT03166527	Phase 3	Immune Globulin 10% Intravenous Solution
4	A Single-arm Study to Demonstrate the Efficacy and Safety of Privigen in the Treatment of Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	Completed	NCT01184846	Phase 3
5	NPB-01(Intravenous Immunoglobulin) Maintenance Therapy for Patients With Chronic Inflammatory Demyelinating Polyneuropathy.	Completed	NCT01824251	Phase 3	NPB-01
6	Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating Polyneuropathy	Completed	NCT00004939	Phase 3	,4-diaminopyridine
7	Multicentre Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg in Patients With Chronic Inflammatory Demyelinating Polyneuropathy on a One Year Follow up	Completed	NCT01349270	Phase 3	Immunoglobulin perfusion;Prednisone
8	Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy	Completed	NCT00004772	Phase 3	Immune globulin
9	An International, Multicentre, Efficacy and Safety Study of I10E in Initial and Maintenance Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy.	Completed	NCT02293460	Phase 3	I10E
10	Multicenter, Open-label Extension Study to Investigate the Long-term Safety and Efficacy of IgPro20 in Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Subjects Completing Study IgPro20_3003	Completed	NCT02027701	Phase 3
11	Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study	Completed	NCT01545076	Phase 3
12	Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating Neuropathy	Completed	NCT00004286	Phase 3	immune globulin
13	Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of IGIV-Chromatography (IGIV-C), 10% Treatment in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy	Completed	NCT00220740	Phase 3	Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified;Albumin (Human) 25%, United States Pharmacopeia (USP)
14	International, Multicentre, Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Extension of PRISM Study I10E-1302"	Terminated	NCT02317562	Phase 3	I10E
15	SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study	Unknown status	NCT02967679	Phase 1, Phase 2	MD1003
16	Lipoic Acid for Chronic Inflammatory Demyelinating Polyneuropathy—A Randomized, Double-Blind, Placebo Controlled Pilot Study	Completed	NCT00962429	Phase 2	lipoic acid
17	The Efficacy of High-Dose Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	Completed	NCT00001287	Phase 2	intravenous immunoglobulin (IVIg)
18	Intravenous Immunoglobulin Therapy for Small Fiber Neuropathy: a Randomized, Double-blind, Placebo-controlled Study on Efficacy and Safety.	Completed	NCT02637700	Phase 2	Intravenous Immunoglobulin;Placebo
19	Safety, Tolerability, and Efficacy of Rituximab in Patients With Anti-Glycoconjugate Antibody-Mediated Demyelinating Neuropathy: A Double-Blind Placebo-Controlled Randomized Trial	Completed	NCT00050245	Phase 2	Rituximab
20	A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	Recruiting	NCT04281472	Phase 2
21	The Evaluation of Efficacy and Safety of Rituximab (Genetical Recombination) in Refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients With Immunoglobulin G4 (IgG4) Autoantibodies in the Exploratory Clinical Trial	Active, not recruiting	NCT03864185	Phase 2
22	Non-myeloablative Autologous Hematopoietic Stem Cell Transplantation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy: A Phase II Trial	Active, not recruiting	NCT00278629	Phase 2
23	Non-myeloablative Hematopoietic Stem Cell Transplantation for Stiff Person Syndrome (SPS) and Anti-GAD Antibody Variants: Progressive Encephalomyelitis With Rigidity and Myoclonus (PERM), and Adult Onset Autoimmune Anti-GAD Positive Cerebellar Ataxia	Active, not recruiting	NCT02282514	Phase 1, Phase 2	Cyclophosphamide;Mesna;rATG;Methylprednisolone;G-CSF;Rituxan
24	Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	Not yet recruiting	NCT04280718	Phase 2
25	Intravenous Immunoglobulin (IVIG) in the Treatment of Autoimmune Small Fiber Neuropathy Due to TS-HDS and FGFR-3 Antibodies: a Double Blinded Placebo-controlled Phase II Trial	Not yet recruiting	NCT04153422	Phase 2	Gammagard IVIG;Placebo
26	Thrombolysis in Ischemic Spinal Cord Stroke	Terminated	NCT02242084	Phase 2	Intravenuse Alteplase
27	Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy	Withdrawn	NCT02574962	Phase 2	H.P. Acthar® Gel
28	A Phase II Trial of High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy	Withdrawn	NCT01236456	Phase 2	Cyclophosphamide
29	Electromyography Evaluation of the Stabilizing Muscles of the Scapula and Tibial Anterior Muscle, After an Intervention Program by Proprioceptive Neuromuscular Facilitation in Muscle Force Irradiation.	Unknown status	NCT02255708	Phase 1
30	Quantification of Nerve Stiffness in Patients With Peripheral Neuropathies	Unknown status	NCT03397303
31	A Study of Subcutaneous Immunoglobulin as Chronic Treatment for Patients With Chronic Inflammatory Demyelinating Polyneuropathy	Unknown status	NCT02465359		Immune Globulin Subcutaneous (Human)
32	sCD163 as a Potential Biomarker in Guillain- Barré Syndrome	Unknown status	NCT02582853
33	sCD163 & CD19 as Candidate Biomarkers in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - A Study of sCD163 in the Cerebrospinal Fluid	Unknown status	NCT02271724
34	A Multicenter Pilot Study to Determine Criteria for Evaluating the Effectiveness of Two Comparative Monitoring Methods in the Management of Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Receiving Home-based Treatment With IVIg (Privigen®)	Completed	NCT03779828
35	Effect of Resistance and Aerobic Exercise on Muscle Strength, Aerobic Capacity and Quality of Life in Patients Treated With Immunoglobulin for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) or Multifocal Motor Neuropathy (MMN)	Completed	NCT02121678
36	The Influence of Immunoglobulin Dosage and Administration on Development of Hemolytic Anemia and Variation on Muscle Strength in Patients With CIDP and MMN	Completed	NCT02111590		Immunoglobulins
37	Observational Study of the Prevalence of Some Genetic Mutations in Patients With Neuropathy Associated With Anti-Myelin-associated Glycoprotein (MAG) Antibodies.	Completed	NCT03268161
38	Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy	Completed	NCT01379833
39	A Multi-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-Directed Biomedical Research Initiatives	Recruiting	NCT01931644
40	Descriptive Analysis of Morphological Aspects of Nerve by Ultra-high Frequency Ultrasound (30-50MHZ) in Demyelinating Neuropathies: Inflammatory Demyelinating Polyneuropathy Chronic (IPDC), Neuropathy Multifocal Motor Block of Conducting (NMMBC) and Neuropathy With Antibody A MAG	Recruiting	NCT03008733
41	Intravenous Immunoglobulin (IVIg) Treatment-Related Fluctuations in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients Using Daily Grip Strength Measurements (GRIPPER)	Active, not recruiting	NCT02414490		Intravenous Immunoglobulin
42	A Registered Cohort Study of Immune-Mediated Neuropathies	Not yet recruiting	NCT04292834
43	Study of Gait and Posture in Subacute Acquired Neuropathies and in Hereditary Neuropathies	Not yet recruiting	NCT04154540
44	Non-invasive Vagus Nerve Stimulation (nVNS) in Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	Not yet recruiting	NCT03772717		Standard of Care
45	Investigation of Plastic Changes in the CNS Associated With Peripheral Neuropathy	Not yet recruiting	NCT03805893

Search NIH Clinical Center for Demyelinating Polyneuropathy

Sources

Genetic Tests for Demyelinating Polyneuropathy

Sources

Anatomical Context for Demyelinating Polyneuropathy

MalaCards organs/tissues related to Demyelinating Polyneuropathy:

⁴⁰

T Cells, Spinal Cord, Testes, Brain, Skin, Bone, B Cells

Sources

Publications for Demyelinating Polyneuropathy

Articles related to Demyelinating Polyneuropathy:

(show top 50) (show all 2364)

#	Title	Authors	PMID	Year
1	Abnormal motor unit firing rates in chronic inflammatory demyelinating polyneuropathy. ⁶¹	Gilmore KJ...Rice CL	32402831	2020
2	Motor chronic inflammatory demyelinating polyneuropathy (CIDP) in 17 patients: Clinical characteristics, electrophysiological study, and response to treatment. ⁶¹	Pegat A...Viala K	32364302	2020
3	Low interrater reliability of brachial plexus MRI in chronic inflammatory neuropathies. ⁶¹	van Rosmalen MHJ...van der Pol WL	32012299	2020
4	Efficacy of low dose rituximab in treatment-resistant CIDP with antibodies against NF-155. ⁶¹	Jiao L...Guo S	32563125	2020
5	The Misdiagnosis of CIDP: A Review. ⁶¹	Allen JA	32219701	2020
6	Neurological complications associated with influenza in season 2017/18 in Austria- a retrospective single center study. ⁶¹	Mylonaki E...Wipfler P	32302952	2020
7	High-Resolution Nerve Ultrasound to Assess Nerve Echogenicity, Fascicular Count, and Cross-Sectional Area Using Semiautomated Analysis. ⁶¹	Gamber D...Fisse AL	32521091	2020
8	What Can Mimic Multiple Sclerosis? ⁶¹	Jewells VL...Latchaw RE	32448485	2020
9	Genotype-phenotype correlation in a novel ABHD12 mutation underlying PHARC syndrome. ⁶¹	Thimm A...Stettner M	32077159	2020
10	A review of pathophysiology and neuropsychiatric manifestations of COVID-19. ⁶¹	Jasti M...Onteddu S	32494854	2020
11	Recurrent Demyelinating Episodes as Sole Manifestation of Inherited CD59 Deficiency. ⁶¹	Solmaz I...Anlar B	31752029	2020
12	Acute Demyelinating Polyneuropathy in a Child with Dengue Shock Syndrome. ⁶¹	Kumar S...Angurana SK	32542487	2020
13	BAG3 Myopathy Presenting With Prominent Neuropathic Phenotype and No Cardiac or Respiratory Involvement: A Case Report and Literature Review. ⁶¹	Malatesta L...Veerapandiyan A	32453099	2020
14	Guillain-Barré syndrome during SARS-CoV-2 pandemic: A case report and review of recent literature. ⁶¹	Scheidl E...Bereznai B	32388880	2020
15	Electrodiagnostic accuracy in polyneuropathies: supervised learning algorithms as a tool for practitioners. ⁶¹	Uncini A...Ippoliti L	32518996	2020
16	Ultrastructural mechanisms of macrophage-induced demyelination in Guillain-Barré syndrome. ⁶¹	Koike H...Sobue G	32245766	2020
17	Pathophysiology of Chronic Inflammatory Demyelinating Polyneuropathy: Insights into Classification and Therapeutic Strategy. ⁶¹	Koike H...Katsuno M	32410146	2020
18	Acute inflammatory demyelinating polyneuropathy following interruption of antiretroviral treatment and HIV rebound. ⁶¹	Malano D...Podzamczer D	31998944	2020
19	High Levels of Il-19 in Patients with Chronic Inflammatory Demyelinating Polyneuropathy. ⁶¹	Sangsefidi S...Eftekharian MM	32472395	2020
20	Quantitative sudomotor test helps differentiate transthyretin familial amyloid polyneuropathy from chronic inflammatory demyelinating polyneuropathy. ⁶¹	Fortanier E...Attarian S	32217467	2020
21	Clinical correlates of fatigue in chronic inflammatory demyelinating polyneuropathy. ⁶¹	Lawley A...Rajabally YA	32388856	2020
22	Rituximab for chronic inflammatory demyelinating polyneuropathy-A potential therapeutic option. ⁶¹	Cohen JC...Lewis RA	32232860	2020
23	Rituximab in refractory chronic inflammatory demyelinating polyneuropathy. ⁶¹	Muley SA...Dimachkie MM	31922613	2020
24	Assessment of IL-38 Levels in Patients with Acquired Immune-Mediated Polyneuropathies. ⁶¹	Ali ZPM...Eftekharian MM	32367504	2020
25	Long-term treatment with subcutaneous immunoglobulin in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a follow-up period up to 7 years. ⁶¹	Gentile L...Toscano A	32404895	2020
26	Immunomodulatory and anti-oxidative effect of the direct TRPV1 receptor agonist capsaicin on Schwann cells. ⁶¹	Gruter T...Pitarokoili K	32375895	2020
27	Clinical features of Guillain-Barré syndrome patients with elevated serum creatine kinase levels. ⁶¹	Hosokawa T...Arawaka S	32460711	2020
28	Comparison of the Clinical Outcomes of Guillain Barre Syndrome Based on Electrophysiological Subtypes in Pakistani Children. ⁶¹	Parveen A...Hussain SNF	32537271	2020
29	A novel frameshift mutation in SOX10 causes Waardenburg syndrome with peripheral demyelinating neuropathy, visual impairment and the absence of Hirschsprung disease. ⁶¹	Burke EA...Adams D	32150337	2020
30	A case of combined central and peripheral demyelination in Zambia. ⁶¹	George IC...Saylor D	31958671	2020
31	Different distribution of demyelination in chronic inflammatory demyelinating polyneuropathy subtypes. ⁶¹	Shibuya K...Kuwabara S	32006783	2020
32	[Pitfalls for Diagnosis of Polyneuropathy by Nerve Conduction Study]. ⁶¹	Misawa S	32284466	2020
33	Use of Magnetic Resonance Neurography for Evaluating the Distribution and Patterns of Chronic Inflammatory Demyelinating Polyneuropathy. ⁶¹	Su X...Zheng C	32193896	2020
34	Chronic Inflammatory Demyelinating Polyneuropathy: Time to Maximal Recovery in Patients Receiving Intravenous Immunoglobulin Therapy. ⁶¹	Opala AR...Baker SK	32279669	2020
35	Epidemiology of chronic inflammatory demyelinating polyneuropathy in the South-Eastern area of Santiago, Chile. ⁶¹	Cea G...Stuardo A	32067826	2020
36	Antibody- and macrophage-mediated segmental demyelination in chronic inflammatory demyelinating polyneuropathy: clinical, electrophysiological, immunological and pathological correlates. ⁶¹	Vallat JM...Devaux J	31769579	2020
37	Monitoring Clinical Course and Treatment Response in Chronic Inflammatory Demyelinating Polyneuropathy During Routine Care: A Review of Clinical and Laboratory Assessment Measures. ⁶¹	Allen JA...Lewis RA	32338716	2020
38	Diagnosing peripheral neuropathy in South-East Asia: A focus on diabetic neuropathy. ⁶¹	Malik RA...Wong KS	32268012	2020
39	Nerve ultrasound improves detection of treatment-responsive chronic inflammatory neuropathies. ⁶¹	Herraets IJT...van der Pol WL	31959710	2020
40	Combined intravenous immunoglobulin and methylprednisolone as induction treatment in chronic inflammatory demyelinating polyneuropathy (OPTIC protocol): a prospective pilot study. ⁶¹	Adrichem ME...Eftimov F	31571349	2020
41	Seronegative occult HBV reactivation complicated with fulminant acute liver failure after rituximab for chronic inflammatory demyelinating polyneuropathy. ⁶¹	Buonomo AR...Gentile I	31766959	2020
42	Co-occurrence of Merkel Cell Carcinoma and Chronic Inflammatory Demyelinating Polyneuropathy. ⁶¹	Kuo AM...Barker CA	32159728	2020
43	A population-based study of long-term outcome in treated chronic inflammatory demyelinating polyneuropathy. ⁶¹	Al-Zuhairy A...Jakobsen J	31793666	2020
44	Diagnosis and treatment of Guillain-Barré Syndrome in childhood and adolescence: An evidence- and consensus-based guideline. ⁶¹	Korinthenberg R...Muller-Felber W	31941581	2020
45	Autoimmune Peripheral Neuropathies and Contribution of Antiganglioside/Sulphatide Autoantibody Testing. ⁶¹	Roggenbuck D...Boucraut J	32411930	2020
46	Treatment-related fluctuations in subacute inflammatory demyelinating polyneuropathy. ⁶¹	Min YG...Hong YH	32055719	2020
47	Treatment of painful polyneuropathies of diabetic and other origins with 10 kHz SCS: a case series. ⁶¹	Sills S	32073352	2020
48	Cerebrospinal fluid total protein in Guillain-Barré syndrome variants: correlations with clinical category, severity, and electrophysiology. ⁶¹	Bourque PR...Breiner A	31734909	2020
49	Axonal variants of Guillain-Barré syndrome: an update. ⁶¹	Shang P...Zhang HL	32140865	2020
50	Hyper-reflexia in Guillain-Barré syndrome: systematic review. ⁶¹	Uncini A...Kuwabara S	31937584	2020

Sources

Genes for Demyelinating Polyneuropathy

Genes related to Demyelinating Polyneuropathy (0 elite genes):

(show all 24)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	PMP22	Peripheral Myelin Protein 22	Protein Coding	24.6	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications (show sections)
2	NFASC	Neurofascin	Protein Coding	15.03	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
3	MAG	Myelin Associated Glycoprotein	Protein Coding	14.68	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
4	CNTN1	Contactin 1	Protein Coding	14.09	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
5	TTR	Transthyretin	Protein Coding	12.85	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
6	CNTN2	Contactin 2	Protein Coding	12.59	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	FCGR2B	Fc Fragment Of IgG Receptor IIb	Protein Coding	12.57	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
8	ALB	Albumin	Protein Coding	12.39	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
9	NGF	Nerve Growth Factor	Protein Coding	11.59	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	TNFSF13B	TNF Superfamily Member 13b	Protein Coding	11.27	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
11	CLDN5	Claudin 5	Protein Coding	11.24	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
12	AIF1	Allograft Inflammatory Factor 1	Protein Coding	11.24	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
13	HP	Haptoglobin	Protein Coding	11.01	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
14	GAS6	Growth Arrest Specific 6	Protein Coding	10.91	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
15	AIRE	Autoimmune Regulator	Protein Coding	10.86	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
16	CD52	CD52 Molecule	Protein Coding	10.84	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
17	IFNA2	Interferon Alpha 2	Protein Coding	10.72	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
18	MMP9	Matrix Metallopeptidase 9	Protein Coding	10.72	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
19	PTGDS	Prostaglandin D2 Synthase	Protein Coding	10.58	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
20	GDNF	Glial Cell Derived Neurotrophic Factor	Protein Coding	10.47	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
21	CXCL9	C-X-C Motif Chemokine Ligand 9	Protein Coding	10.4	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
22	CD1D	CD1d Molecule	Protein Coding	10.35	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
23	IL18	Interleukin 18	Protein Coding	10.28	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
24	TJP1	Tight Junction Protein 1	Protein Coding	10.22	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)

Sources

Variations for Demyelinating Polyneuropathy

ClinVar genetic disease variations for Demyelinating Polyneuropathy:

⁶ ‎‎

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	GRCh37 Pos	GRCh38 Pos
1	KIF5A	NM_004984.4(KIF5A):c.2005G>A (p.Ala669Thr)	SNV	Uncertain significance	816537		12:57969522-57969522	12:57575739-57575739

Sources

Expression for Demyelinating Polyneuropathy

Search GEO for disease gene expression data for Demyelinating Polyneuropathy.

Sources

Pathways for Demyelinating Polyneuropathy

Pathways related to Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Cell adhesion molecules (CAMs) ³⁶	11.52	NFASC MAG CNTN2 CNTN1 CLDN5
2	Spinal Cord Injury ¹	11.1	TNFSF13B MMP9 MAG GDNF AIF1

Sources

GO Terms for Demyelinating Polyneuropathy

Cellular components related to Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular region	GO:0005576	9.9	TTR TNFSF13B PTGDS NGF MMP9 IFNA2
2	extracellular space	GO:0005615	9.65	TTR TNFSF13B PTGDS NGF MMP9 IFNA2
3	node of Ranvier	GO:0033268	9.4	NFASC CNTN2
4	Schmidt-Lanterman incisure	GO:0043220	9.37	MAG CLDN5
5	compact myelin	GO:0043218	9.32	PMP22 MAG
6	anchored component of postsynaptic membrane	GO:0099025	9.26	CNTN2 CNTN1
7	paranode region of axon	GO:0033270	8.8	NFASC MAG CLDN5

Biological processes related to Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	myelination	GO:0042552	9.5	PMP22 NFASC CLDN5
2	cerebellum development	GO:0021549	9.43	FCGR2B CNTN1 AIF1
3	negative regulation of apoptotic process	GO:0043066	9.43	NGF MMP9 GDNF GAS6 ALB AIF1
4	central nervous system myelination	GO:0022010	9.37	MAG CNTN2
5	protein localization to juxtaparanode region of axon	GO:0071205	9.16	NFASC CNTN2
6	peripheral nervous system development	GO:0007422	8.92	PMP22 NGF NFASC GDNF

Molecular functions related to Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	signaling receptor binding	GO:0005102	9.02	TNFSF13B NGF MAG GDNF GAS6

Sources

Sources for Demyelinating Polyneuropathy

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NIH Rare Diseases

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM

⁵⁷ OMIM via Orphanet

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ TGDB

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ Wikipedia